JP2025525990A5 - - Google Patents
Info
- Publication number
- JP2025525990A5 JP2025525990A5 JP2025507001A JP2025507001A JP2025525990A5 JP 2025525990 A5 JP2025525990 A5 JP 2025525990A5 JP 2025507001 A JP2025507001 A JP 2025507001A JP 2025507001 A JP2025507001 A JP 2025507001A JP 2025525990 A5 JP2025525990 A5 JP 2025525990A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- bdnf
- composition according
- concentration
- hearing loss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22189067.6 | 2022-08-05 | ||
| EP22189067.6A EP4316462A1 (en) | 2022-08-05 | 2022-08-05 | Intranasal administration of bdnf for the treatment of sensorineural hearing loss |
| PCT/EP2023/071676 WO2024028483A1 (en) | 2022-08-05 | 2023-08-04 | Intranasal administration of bdnf for the treatment of sensorineural hearing loss |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025525990A JP2025525990A (ja) | 2025-08-07 |
| JP2025525990A5 true JP2025525990A5 (https=) | 2026-05-07 |
Family
ID=83080998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025507001A Pending JP2025525990A (ja) | 2022-08-05 | 2023-08-04 | 感音難聴の治療のためのｂｄｎｆの鼻腔内投与 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20260048006A1 (https=) |
| EP (2) | EP4316462A1 (https=) |
| JP (1) | JP2025525990A (https=) |
| CN (1) | CN119816318A (https=) |
| AU (1) | AU2023317860A1 (https=) |
| CA (1) | CA3263977A1 (https=) |
| IL (1) | IL318653A (https=) |
| WO (1) | WO2024028483A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4623926A1 (en) * | 2024-03-26 | 2025-10-01 | Dompe' Farmaceutici SpA | Intranasal administration of bdnf for treatment of primary headaches |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2278999B1 (en) * | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| WO2019140012A1 (en) * | 2018-01-09 | 2019-07-18 | Otonomy, Inc. | Growth factor otic formulations |
| WO2021030452A1 (en) * | 2019-08-14 | 2021-02-18 | Decibel Therapeutics, Inc. | Permeation enhancers, compositions containing them, and methods of using the same |
| WO2021151013A1 (en) * | 2020-01-24 | 2021-07-29 | Otonomy, Inc. | Growth factor formulation for condition associated with otic event |
| US20240066099A1 (en) * | 2020-12-15 | 2024-02-29 | Dompé Farmaceutici S.P.A. | Bdnf otic formulations and use thereof |
-
2022
- 2022-08-05 EP EP22189067.6A patent/EP4316462A1/en not_active Withdrawn
-
2023
- 2023-08-04 JP JP2025507001A patent/JP2025525990A/ja active Pending
- 2023-08-04 EP EP23753876.4A patent/EP4565254A1/en active Pending
- 2023-08-04 WO PCT/EP2023/071676 patent/WO2024028483A1/en not_active Ceased
- 2023-08-04 AU AU2023317860A patent/AU2023317860A1/en active Pending
- 2023-08-04 CA CA3263977A patent/CA3263977A1/en active Pending
- 2023-08-04 IL IL318653A patent/IL318653A/en unknown
- 2023-08-04 US US19/100,783 patent/US20260048006A1/en active Pending
- 2023-08-04 CN CN202380063429.2A patent/CN119816318A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025142338A5 (https=) | ||
| AU2007298814B2 (en) | Galenic form for the trans-mucosal delivery of active ingredients | |
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2024170583A5 (https=) | ||
| ES2963348T3 (es) | Métodos para tratar la osificación heterotópica | |
| HUP0202862A2 (hu) | A loteprednol és antihisztaminok új kombinációját tartalmazó gyógyszerkészítmény | |
| JP2023550149A5 (https=) | ||
| JP2023500032A5 (https=) | ||
| JP2025525989A5 (https=) | ||
| JP2024516363A5 (https=) | ||
| JP2025525990A5 (https=) | ||
| JP2023115271A5 (https=) | ||
| JP2025166240A5 (https=) | ||
| JP2022534776A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| JP2023520703A5 (https=) | ||
| JP2024540439A5 (https=) | ||
| US5925625A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| CN1255849A (zh) | 药用组合物 | |
| BR112019026029A2 (pt) | Formulações farmacêuticas orais de remogliflozina | |
| RU2025104605A (ru) | Интраназальное введение нфгм для лечения сенсоневральной тугоухости | |
| JP2022526643A5 (https=) | ||
| EP2959891A1 (en) | Modified release pharmaceutical compositions of sofosbuvir and ribavirin | |
| JP2022550734A5 (https=) | ||
| JP2025522146A5 (https=) |